Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. 01099
01099 logo

01099 Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
21.620
Open
21.540
VWAP
21.17
Vol
3.55M
Mkt Cap
--
Low
21.000
Amount
75.25M
EV/EBITDA(TTM)
6.47
Total Shares
--
EV
18.91B
EV/OCF(TTM)
--
P/S(TTM)
0.10

Events Timeline

No data

No data

News

aastocks
9.5
03-23aastocks
SINOPHARM Reports 1.5% Increase in Annual NP to RMB7.155 Billion; Final Dividend Set at RMB0.69
  • Stock Performance: SINOPHARM (01099.HK) experienced a decrease of 0.260, reflecting a decline of 1.246% in its stock price.
  • Short Selling Activity: The company reported short selling of $19.77 million, with a short selling ratio of 19.074%.
  • Annual Results Announcement: SINOPHARM has announced its annual results for the fiscal year ending December 2025.
  • Market Context: The financial performance and short selling figures indicate ongoing market interest and potential volatility surrounding the company's stock.
aastocks
6.5
03-06aastocks
M Stanley's Recommended Defensive Stocks for HK Amid Geopolitical Uncertainty (Table)
  • Morgan Stanley Report: Morgan Stanley has identified a list of Defensive Stocks in the Asia-Pacific region, particularly focusing on Hong Kong stocks that offer high dividends, low volatility, and an Overweight rating.

  • Highlighted Stocks: The report includes several stocks such as China Tower, Bosideng, Midea Group, and various banks like CCB and Bank of China, along with their short selling data and performance metrics.

aastocks
4.5
02-25aastocks
<Daily Summary> HSI Ends at 26,765, Gaining 175 Points; HSTI Finishes at 5,260, Dropping 10 Points; HAIDILAO Surges Over 6%; HSBC HOLDINGS, TINGYI, SINOPHARM, TIME INTERCON, and WANGUO GOLD GP Reach New Peaks; Market Turnover Increases
  • Market Performance: The Hang Seng Index (HSI) rose by 175 points (0.7%) to 26,765, while the Hang Seng Technology Index (HSTI) fell by 10 points (0.2%) to 5,260, and the Hang Seng China Enterprises Index (HSCEI) increased by 26 points (0.3%) to 9,034, with a total market turnover of $236.77 billion.

  • Active Heavyweights: Notable stock movements included PING AN (+1.9%), MEITUAN (+1.6%), and TENCENT (+0.5%), while XIAOMI (-0.4%) and HKEX (-0.3%) saw declines.

  • Significant Gainers: HAIDILAO surged by 6.2%, HSBC HOLDINGS rose by 5.5% to a new high, and LONGFOR increased by 4.6%, while XINYI SOLAR and WH GROUP experienced declines of 3.6% and 3.3%, respectively.

  • Noteworthy Stocks: RIMAG GROUP dropped significantly by 10.6%, while TIME INTERCON and WANGUO GOLD GP saw increases of 10.2% and 6.9%, respectively, with both hitting new highs.

aastocks
4.5
02-25aastocks
Midday Update: HSI Ends at 26,789, Gaining 199 Points; HSTI Reaches 5,288, Up 17 Points; HAIDILAO Surges Over 5%; LI NING, SINOPHARM, CHINA RES MIXC, HENGAN INT'L, and MTR CORPORATION Achieve New Highs
  • Market Performance: The Hang Seng Index (HSI) rose by 199 points (0.8%) to 26,789, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains of 17 points (0.3%) and 81 points (0.9%) respectively.

  • Active Heavyweights: Notable stocks included Meituan, Ping An, Tencent, and Alibaba, all experiencing increases in their share prices, with Meituan leading at a 2.3% rise.

  • Top Gainers: Among HSI and HSCEI constituents, Haidilao and Longfor showed significant gains of 5.8% and 4.6% respectively, while Xinyi Solar was the only notable loser, dropping by 3.0%.

  • Short Selling Activity: High short selling ratios were observed in several stocks, with Ping An and China Resources Land having ratios of 35.649% and 40.187% respectively, indicating significant market speculation.

aastocks
4.5
02-24aastocks
<Full-day Summary> HSI Falls by 491 Points; HSTI Declines by 114 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, MTR CORPORATION, SINOPHARM Reach New Peaks; Market Turnover Increases
  • Market Performance: The Hang Seng Index (HSI) fell by 491 points (1.8%) to close at 26,590, with significant declines also seen in the HSTI and HSCEI, which dropped 114 points (2.1%) and 189 points (2.1%) respectively, amid a market turnover of $250.99 billion.

  • Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, Alibaba, and Xiaomi experienced notable declines, with Meituan down 4.2% and Tencent down 3.3%, reflecting a trend of short selling across these companies.

  • Constituents on the Move: Several constituents saw significant price changes, including Sino Biopharma and Hansoh Pharma, which dropped 6.6% and 6.4% respectively, while WH Group rose by 4.4%, reaching a new high.

  • Other Notable Stocks: Stocks such as MIRXES-B and CTG Duty-Free faced substantial losses, with MIRXES-B down 21.7%, while KB Laminates and CNBM saw gains of 12.4% and 10.5%, respectively, also hitting new highs.

aastocks
4.5
02-24aastocks
<Midday Update> HSI Falls 523 Points; HSTI Declines 127 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, SINOPHARM, KB LAMINATES Reach New Peaks
  • Market Performance: The Hang Seng Index (HSI) fell by 523 points (1.9%) to 26,558, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 2.4% and 2.1%, respectively.

  • Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, and Alibaba saw significant drops, with Meituan down 4.8% and Tencent down 3.4%, amidst high short selling ratios.

  • Notable Declines in Constituents: Several constituents, including Hansoh Pharma and Sino Biopharma, reported steep declines, with Hansoh Pharma down 6.5% and Sino Biopharma down 6.1%.

  • Gainers Amidst Losses: Despite the overall market downturn, a few stocks like WH Group and Henderson Land recorded gains, with WH Group up 3.2% and Henderson Land up 1.7%, both hitting new highs.

Wall Street analysts forecast 01099 stock price to rise
0 Analyst Rating
Wall Street analysts forecast 01099 stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
Citi
Buy
maintain
$23
AI Analysis
2026-03-24
Reason
Citi
Price Target
$23
AI Analysis
2026-03-24
maintain
Buy
Reason
Citi maintains a Buy rating for SINOPHARM despite lowering its target price slightly, as the company is expected to stabilize its pharmaceutical distribution business while experiencing positive growth in medical device distribution and retail. Additionally, SINOPHARM's strategic positioning within the Sinopharm Group aims to enhance its service offerings across the healthcare value chain.
HSBC Global Research
HSBC Global Research
Hold
maintain
2025-11-11
Reason
HSBC Global Research
HSBC Global Research
Price Target
2025-11-11
maintain
Hold
Reason
The analyst rating from HSBC Global Research is a Hold for both SH PHARMA and SINOPHARM due to several factors: 1. Lack of Short-Term Catalysts: The commercialization of the Chinese pharmaceutical industry is currently lacking immediate drivers for growth. 2. Weakening Recovery Pace: The recovery of the domestic market is slowing down, which raises concerns about future performance. 3. Policy Uncertainties: Ongoing uncertainties in policies are hindering industry growth, creating an unstable environment for companies. 4. Earnings Growth Pressure: Companies are facing pressure from slowing earnings growth, which they can only partially mitigate through improved operational efficiency. 5. Sector Challenges: Anticipated delays in domestic consumption recovery, the impact of volume-based procurement policies, and tightened medical insurance payments are expected to suppress the sector's short-term upside potential. These factors led to a cautious outlook, resulting in the Hold rating for both companies.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for 01099
Unlock Now

Valuation Metrics

The current forward P/E ratio for (01099.HK) is 6.98, compared to its 5-year average forward P/E of 6.46. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
6.46
Current PE
6.98
Overvalued PE
7.31
Undervalued PE
5.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
5.68
Current EV/EBITDA
6.89
Overvalued EV/EBITDA
6.64
Undervalued EV/EBITDA
4.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.09
Current PS
0.09
Overvalued PS
0.10
Undervalued PS
0.08

Financials

AI Analysis
Annual
Quarterly

Whales Holding 01099

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is (01099) stock price today?

The current price of 01099 is 21.08 USD — it has decreased -1.95

What is (01099)'s business?

What is the price predicton of 01099 Stock?

Wall Street analysts forecast 01099 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01099 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (01099)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (01099)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (01099). have?

(01099) has 0 emplpoyees as of April 11 2026.

What is (01099) market cap?

Today 01099 has the market capitalization of 0.00 USD.